BioCentury | Sep 26, 2016
Clinical News

SRX246: Phase II data

...that twice-daily 120 mg oral SRX246 for 4 weeks followed by twice-daily 160 mg oral SRX246...
...well tolerated with no serious adverse events reported. Azevan Pharmaceuticals Inc. , Bethlehem, Pa. Product: SRX246...
BioCentury | May 16, 2016
Clinical News

SRX246: Completed Phase II enrollment

...U.S. Phase II trial evaluating twice-daily oral SRX246 for 8 weeks. Patients receive 120 mg SRX246...
...and 160 mg for the next 4 weeks. Azevan Pharmaceuticals Inc. , Bethlehem, Pa. Product: SRX246...
Items per page:
1 - 2 of 2